Red Yeast Rice for Statin-associated Myalgia

Verdict: Weak, disputed evidence; not a statin-free fix

The evidence that red yeast rice helps people who get muscle pain from statins is weak and disputed. Its active ingredient, monacolin K, is chemically identical to the statin lovastatin, so it is not a true statin-free alternative and can cause the same muscle, liver, and kidney problems.

C 🟠 C Weak Evidence Disputed

🔬Why this grade7-layer evidence engine

The grade reflects a thin, conflicted evidence base. Only two small single-center randomized trials enrolled confirmed statin-intolerant patients. Becker 2009 (PMID 19528562, n=62) found red yeast rice lowered LDL cholesterol more than placebo (about -35 mg/dL at 24 weeks) with no worse pain or muscle-enzyme readings, but it was not designed to prove the supplement itself is free of muscle pain. Becker/Halbert 2010 (PMID 20102918, n=43) saw similar pain-driven dropout versus low-dose pravastatin (5% vs 9%, p=0.99) — far too few patients to draw a firm conclusion.

The remaining support is off-target. A 2017 pilot (PMID 28521773, n=60) reporting less fatigue than simvastatin enrolled general dyslipidemic patients, not a confirmed statin-intolerant group, and ran only four weeks; the 2014 meta-analysis (PMID 24897342, 804 people) pooled cholesterol trials, not muscle-intolerance cohorts, and its authors call for rigorous long-term studies. The central paradox is that monacolin K is lovastatin, so any apparent 'tolerability' likely reflects a lower or inconsistent statin dose rather than a different mechanism.

Regulators and clinics range from cautious to negative. The US FDA treats red yeast rice with more than trace monacolin K as an unapproved drug, and the EU EFSA restricts the monacolins allowed in supplements. Mayo Clinic warns it shares lovastatin's muscle, liver, and kidney risks, and Harvard Health advises against it. Monacolin content in commercial products is highly variable and unregulated, and citrinin (a kidney-toxic mold byproduct) is a known contamination concern.

⚖️

Scoring transparency

All scores computed by a 7-layer evidence engine — fully auditable

Raw score 0.53

← counter-evidence / ineffectiveeffective / strong evidence →

Final grade

C · Disputed

Confidence

69%

Broadly consistent

Evidence level

Single high-quality meta-analysis

How strongly each layer supports this effect

lower = less supportive

L5 Clinical bodiesAuthoritative stance

0.34

L1 ExamineGlobal benchmark

0.50

L11 AI re-checkIndependent read

0.50

L2 PubMedPrimary literature

0.60

L3 MechanismPlausibility

0.65

Against Mixed Supports

▸View the full decision path (audit trail)

compute_raw_score — 加權公式: L2×0.30 + L3×0.25 + L5×0.25 + L11×0.10 + L1×0.10 = 0.528
tier_from_score — 依分數區間映射至 tier letter
apply_hec_rules — 高品質 SR/MA 顯示 positive (1 篇 > 0 negative)
tier_strict_requirement_check — Tier 條件達標，未降階
detect_disputes — 偵測到 1 個 hard + 0 個 soft dispute
decide_status — 依 tier + dispute 結果決定 status

📄PubMed studies (4)L2 · primary research & systematic reviews

Red yeast rice for dyslipidemia in statin-intolerant patients: a randomized trial

PMID: 19528562 2009 RCT (double-blind) n = 62

Finding: In 62 patients who had previously discontinued a statin because of myalgia, red yeast rice lowered LDL-C significantly more than placebo (-43 mg/dL vs -11 mg/dL at week 12, p<0.001; -35 mg/dL vs -15 mg/dL at week 24, p=0.011). Critically, pain severity scores, CPK and liver enzymes did NOT differ between groups, so the trial was not designed to and did not demonstrate that red yeast rice itself is free of myalgia — it shows efficacy and that pain did not worsen versus placebo over 24 weeks.

Government Effect size: [object Object]

View on PubMed

Tolerability of red yeast rice (2,400 mg twice daily) versus pravastatin (20 mg twice daily) in patients with previous statin intolerance

PMID: 20102918 2010 RCT (open-label) n = 43

Finding: Among 43 adults with prior statin discontinuation for myalgia, withdrawal due to myalgia was 5% (1/21) with red yeast rice versus 9% (2/22) with pravastatin (p=0.99), with no between-group difference in pain severity or muscle strength at weeks 4/8/12 and comparable LDL-C reduction (30% vs 27%). The Becker group concluded red yeast rice was as well tolerated as low-dose pravastatin — but since red yeast rice contains monacolin K (lovastatin), this is a comparison of two statin-class agents, not proof of statin-free tolerability; the small sample also leaves the trial underpowered for myalgia.

🟠 Limited quality Government Effect size: [object Object]

View on PubMed

Red yeast rice induces less muscle fatigue symptom than simvastatin in dyslipidemic patients: a single center randomized pilot trial

PMID: 28521773 2017 RCT (open-label) n = 60

Finding: In 60 low-to-moderate-CV-risk dyslipidemic patients, fatigue scores rose significantly with simvastatin (p<0.001 vs baseline) but not with red yeast rice (p=0.16), and were significantly higher in the simvastatin arm between groups (p<0.01); physical activity declined with simvastatin (p<0.001) but not red yeast rice (p=0.19). This pilot suggests lower-dose red yeast rice causes less muscle fatigue than a moderate-intensity statin, though it enrolled general dyslipidemic patients (not a confirmed statin-intolerant population) and ran only 4 weeks.

🟠 Limited quality Effect size: [object Object]

View on PubMed

A meta-analysis of red yeast rice: an effective and relatively safe alternative approach for dyslipidemia

PMID: 24897342 2014 統合分析 n = 804

Finding: Pooling 13 RCTs (804 participants), red yeast rice significantly reduced LDL-C versus placebo (WMD -0.87 mmol/L, 95% CI -1.03 to -0.71, p<0.001) and the authors reported no serious side effects across trials. This is not a statin-intolerant-specific meta-analysis and the safety claim relies on heterogeneous, mostly short trials with under-powered myalgia ascertainment; the authors themselves caution that long-term rigorous RCTs are needed before recommending red yeast rice as a statin alternative.

Effect size: [object Object]

View on PubMed

🏛️Regulatory & authoritative positionsL4/L5 · FDA / EMA / NIH ODS / Cochrane / Mayo …

L4a US FDA

Against

Red yeast rice products that contain more than trace amounts of monacolin K cannot be sold legally as dietary supplements; if a red yeast rice product has enhanced or added lovastatin — which is structurally identical to monacolin K — it is considered an unapproved new drug and cannot be marketed as a dietary supplement. source↗

L4b EU EFSA

Against

L4d TW TFDA / 衛福部

Supportive

本標準適用之紅麴產品為利用米進行紅麴菌培養並予乾燥，直接製成粉狀、膠囊或錠狀之食品。……每日攝取量所含之monacolin K至少應達四．八毫克，但不得超過十五毫克。……所含之citrinin含量濃度應低於百萬分之二（2 ppm）。 source↗

L5a NIH Office of Dietary Supplements

Cautious

L5b Mayo Clinic

Cautious

The monacolin K in red yeast rice has the same chemical structure as the prescription cholesterol-lowering medicine lovastatin. The supplement and man-made medicine can have similar side effects that are more serious, including liver, muscle and kidney issues. source↗

L5c Cleveland Clinic

Cautious

L5d Harvard Health

Against

L5e Specialty Society (condition-mapped)

Cautious

✓PMID 100% verifiedevery citation checked via NCBI Entrez

🔬4 PubMed studiesindependently re-checked by multiple sub-agents

engine_version: v1.0 claim_id: CLM-COND-statin-myalgia-INT-red-yeast-rice-001 繁體中文版 →